Evaxion Biotech A/S stock is down -15.19% since 30 days ago. The next earnings date is Dec 19, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.
Evaxion Biotech A/S identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma.